← Leaderboards
Phillip P Minar
Cincinnati Childrens Hosp Med Ctr
$3,776,751
Attributed
$3,776,751
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $789.7K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,776,751 · 3
By mechanism
R01$2,803,917 · 1
K23$734,334 · 1
R03$238,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Marie-Dominique Filippi$10,758,550
Others in their field
Top investigators on “S Disease”
- Lawrence Corey · Fred Hutchinson Cancer Center$643,566,627
- Jeffrey P Krischer · University Of South Florida$588,279,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$477,614,997
- David Heimbrook · Leidos Biomedical Research, Inc.$470,438,912
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$389,132,404
Research focus
S DiseaseOperative Surgical ProceduresInnovationNeutrophilCohortMonitorRelapseInfliximabIntestinesResponseTnf GeneBiological MarkersHealingDisease RemissionChildChronicClinical RemissionCrohn&AposGastrointestinal SymptomClinical TrialsEnrollmentExposure ToQuality Of LifeNovel Therapeutics
Grant awards (10)
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease$662,152
R01 · FY2025 · DK · contact PI
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease$642,469
R01 · FY2024 · DK · contact PI
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease$709,626
R01 · FY2023 · DK · contact PI
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease$789,670
R01 · FY2022 · DK · contact PI
Pharmacokinetic Evaluation to Optimize Infliximab Monotherapy with Personalized Pharmacodynamic Biomarkers$119,250
R03 · FY2019 · DK · contact PI
Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBD$189,945
K23 · FY2018 · DK · contact PI
Pharmacokinetic Evaluation to Optimize Infliximab Monotherapy with Personalized Pharmacodynamic Biomarkers$119,250
R03 · FY2018 · DK · contact PI
Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBD$189,945
K23 · FY2017 · DK · contact PI
Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBD$175,500
K23 · FY2016 · DK · contact PI
Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBD$178,944
K23 · FY2015 · DK · contact PI